Who is sponsoring NCT03760653?

NCT03760653 is sponsored by Universidad Europea de Madrid.

What drugs are being tested in NCT03760653?

Interventions in NCT03760653: Physical Exercise and probiotic group, Probiotic group, Placebo group.

What condition does NCT03760653 study?

NCT03760653 studies Breast Cancer Females.

Is NCT03760653 still recruiting?

NCT03760653 is currently withdrawn. Last updated 24 May 2022.

Last reviewed 2022-05-24 · How we verify

NCT03760653: ESICA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Synergic Effects of Physical Activity and Probiotic on Gut Immune System and Quality of Life of Breast Cancer Survivors.

Withdrawn NA Last updated 24 May 2022

What this trial tests

NA trial testing Physical Exercise and probiotic group in Breast Cancer Females. Withdrawn.

Timeline

1 October 2018

Primary endpoint
1 February 2019

31 December 2019

Quick facts

Lead sponsor	Universidad Europea de Madrid
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 October 2018
Primary completion	1 February 2019
Estimated completion	31 December 2019
Sites	1 location across Spain

Drugs / interventions tested

Physical Exercise and probiotic group
Probiotic group
Placebo group

Conditions studied

Breast Cancer Females — all drugs for Breast Cancer Females →

Sponsor

Universidad Europea de Madrid

Who can join

Adults 18 to 80, female only, with Breast Cancer Females. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Physical exercise along with gut microbiota improvement -because of probiotic intake- can improve the quality of life and immune system in breast cancer survivors. This is achieved because exercise improves the muscle mass in cancer patients (often reduced by treatment and/or inactivity), together with the gut microbiota improvement, this stimulates the inmune system function, improving the quality of life of these patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment.
Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, Jimenez-Rodriguez B, et al · · 2020 · cited 132× · PMID 32878124 · DOI 10.3390/cancers12092465
Microbiome and Breast Cancer: New Role for an Ancient Population.
Eslami-S Z, Majidzadeh-A K, Halvaei S, Babapirali F, et al · · 2020 · cited 111× · PMID 32117767 · DOI 10.3389/fonc.2020.00120
The gut microbiota in breast cancer development and treatment: The good, the bad, and the useful!
Nandi D, Parida S, Sharma D. · · 2023 · cited 55× · PMID 37305949 · DOI 10.1080/19490976.2023.2221452
Potential effect of probiotics in the treatment of breast cancer.
Mendoza L. · · 2019 · cited 53× · PMID 31583054 · DOI 10.4081/oncol.2019.422
Exploring the Potential Role of the Gut Microbiome in Chemotherapy-Induced Neurocognitive Disorders and Cardiovascular Toxicity.
Ciernikova S, Mego M, Chovanec M. · · 2021 · cited 32× · PMID 33668518 · DOI 10.3390/cancers13040782
Exploring the impact of gut microbiota and diet on breast cancer risk and progression.
Teng NMY, Price CA, McKee AM, Hall LJ, et al · · 2021 · cited 31× · PMID 33521932 · DOI 10.1002/ijc.33496
The Microbiome and Its Implications in Cancer Immunotherapy.
Choudhry H. · · 2021 · cited 16× · PMID 33401586 · DOI 10.3390/molecules26010206
Potential of the Microbiome as a Biomarker for Early Diagnosis and Prognosis of Breast Cancer.
Jarman R, Ribeiro-Milograna S, Kalle W. · · 2020 · cited 14× · PMID 33408884 · DOI 10.4048/jbc.2020.23.e60

Verify or expand the search:

Other recruiting trials for Breast Cancer Females

Currently open trials in the same condition.

NCT07256769 — Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis · recruiting
NCT07162675 — Step Count and Treatment Response in Neoadjuvant Breast Cancer · recruiting
NCT06781762 — Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer · recruiting
NCT07553702 — Dance Intervention in Breast Cancer Treatment · NA · active not recruiting
NCT06852833 — One-day Mind Programme for Women With Breast Cancer · NA · active not recruiting

Other Universidad Europea de Madrid trials

Trials by the same sponsor.

NCT07506837 — Effects of an HABIT-ILE-Based Intervention in Children With Cerebral Palsy · NA · not yet recruiting
NCT07470268 — Impact of Hypertrophy-oriented Resistance Training on Muscle Mass and Quality of Life in Patients With Unresectable Panc · NA · not yet recruiting
NCT07494903 — Effects of Vibrational Therapy on Pelvic Floor Muscle Strength and Tone in Healthy Women · NA · not yet recruiting
NCT07524010 — Multi-Omics Characterization of Percutaneous Electrolysis in Low Back Pain · Phase 1 · enrolling by invitation
NCT07484776 — Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03760653 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Europea de Madrid
Last refreshed: 24 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03760653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing